Business Context and Reporting Period
Penumbra, Inc. filed this Form 8-K on March 16, 2017, to report the entry into a material definitive agreement regarding a public offering of common stock. The transaction closed on March 22, 2017.
Key Financial Metrics
- Shares Issued: 1,495,000 shares of common stock (including the full exercise of the underwriters' option to purchase an additional 195,000 shares).
- Net Proceeds: Approximately $106.8 million (after underwriting discounts and commissions, before estimated offering expenses).
- Use of Proceeds: General corporate purposes, working capital, product development (R&D and clinical trials), potential acquisitions, and other business opportunities.
- Liquidity Strategy: Pending use, proceeds will be invested in investment-grade, interest-bearing securities.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels as this is a transaction report rather than a periodic financial statement.
Material Changes
The primary material change is the increase in equity capital and cash liquidity resulting from the sale of 1,495,000 shares. The filing does not provide comparative financial data to quantify changes in operating metrics versus prior periods.
Guidance, Outlook, and Risks
Management intends to utilize the capital for growth initiatives, specifically R&D, clinical trials, and potential acquisitions. The filing notes that certain underwriters (J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated) have provided and currently provide commercial banking services to the Company for customary compensation. No specific forward-looking financial guidance or new risk factors were disclosed in this specific filing.
Investor Verification Checklist
- Verify the final offering price per share to calculate the total gross proceeds.
- Review the full Underwriting Agreement (Exhibit 1.1) for lock-up periods and specific underwriting terms.
- Confirm the exact amount of estimated offering expenses to determine the final net cash inflow.
- Monitor subsequent filings for details on the deployment of proceeds into acquisitions or specific R&D projects.